
Anti-CD22 Therapies - Pipeline Insight, 2025
Description
DelveInsight’s, “Anti-CD22 Therapies - Pipeline Insight, 2025” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Anti-CD22 Therapies pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Anti-CD22 Therapies: Overview
CD22 (Siglec 2) is a single-spanning membrane glycoprotein of 140 kDa on the surface of B cells. Plasma cells do not express the molecule. CD22 has seven extracytoplasmic Ig-like domains and belongs to the Ig superfamily. It serves as a receptor for carbohydrate determinants on a wide variety of cell surface and soluble molecules in vivo. In contrast to CD19, CD22 can act as an antagonist to B cell activation most likely by enhancing the threshold of BCR induced signals. CD22 is expressed on the surface of most B-cell leukemias and lymphomas and therefore has been explored as a target for Ab-based therapies. Research studies shows that use of chimeric antigen receptor (CAR) T-cell therapy, specific for CD22 was reported to provide high response rates for patients with B-cell acute lymphoblastic leukemia (B-ALL) who had failed chemotherapy and/or a CD19-targeted CAR T-cell treatment. The ability of CD22 to regulate both BCR and TLRs represents an attractive therapeutic strategy for manipulating B cell responses in autoimmunity.
Report Highlights
This segment of the Anti-CD22 Therapies report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Anti-CD22 Therapies Emerging Drugs
Further product details are provided in the report……..
Anti-CD22 Therapies: Therapeutic Assessment
This segment of the report provides insights about the different Anti-CD22 Therapies drugs segregated based on following parameters that define the scope of the report, such as:
Anti-CD22 Therapies: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Anti-CD22 Therapies therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Anti-CD22 Therapies drugs.
Anti-CD22 Therapies Report Insights
Current Scenario and Emerging Therapies:
Geography Covered
- Global coverage
Anti-CD22 Therapies: Overview
CD22 (Siglec 2) is a single-spanning membrane glycoprotein of 140 kDa on the surface of B cells. Plasma cells do not express the molecule. CD22 has seven extracytoplasmic Ig-like domains and belongs to the Ig superfamily. It serves as a receptor for carbohydrate determinants on a wide variety of cell surface and soluble molecules in vivo. In contrast to CD19, CD22 can act as an antagonist to B cell activation most likely by enhancing the threshold of BCR induced signals. CD22 is expressed on the surface of most B-cell leukemias and lymphomas and therefore has been explored as a target for Ab-based therapies. Research studies shows that use of chimeric antigen receptor (CAR) T-cell therapy, specific for CD22 was reported to provide high response rates for patients with B-cell acute lymphoblastic leukemia (B-ALL) who had failed chemotherapy and/or a CD19-targeted CAR T-cell treatment. The ability of CD22 to regulate both BCR and TLRs represents an attractive therapeutic strategy for manipulating B cell responses in autoimmunity.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Anti-CD22 Therapies R&D. The therapies under development are focused on novel approaches for Anti-CD22 Therapies.
This segment of the Anti-CD22 Therapies report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Anti-CD22 Therapies Emerging Drugs
- SM03: SinoMab Bioscience
- AUTO3: Autolus
Further product details are provided in the report……..
Anti-CD22 Therapies: Therapeutic Assessment
This segment of the report provides insights about the different Anti-CD22 Therapies drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on Anti-CD22 Therapies
- Phases
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
Anti-CD22 Therapies: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Anti-CD22 Therapies therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Anti-CD22 Therapies drugs.
Anti-CD22 Therapies Report Insights
- Anti-CD22 Therapies Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing Anti-CD22 Therapies drugs?
- How many Anti-CD22 Therapies drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for Anti-CD22 Therapies?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Anti-CD22 Therapies therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Anti-CD22 Therapies and their status?
- What are the key designations that have been granted to the emerging drugs?
- SinoMab Bioscience
- Autolus
- Shanghai Unicar-Therapy Bio-medicine Technology
- Cellectis
- Allife Medical Science and Technology
- SM03
- AUTO3
- Anti CD22 chimeric antigen receptor T cell therapy
- UCART 22
- Anti-CD22 CAR NK Cells
Table of Contents
60 Pages
- Introduction
- Executive Summary
- Anti-CD22 Therapies: Overview
- Structure
- Mechanism of Action
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Anti-CD22 Therapies – DelveInsight’s Analytical Perspective
- In-depth Commercial Assessment
- Anti-CD22 Therapies companies’ collaborations, Licensing, Acquisition -Deal Value Trends
- Anti-CD22 Therapies Collaboration Deals
- Company-Company Collaborations (Licensing / Partnering) Analysis
- Company-University Collaborations (Licensing / Partnering) Analysis
- Late Stage Products (Phase III)
- Comparative Analysis
- SM03: SinoMab Bioscience
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- Anti CD22 chimeric antigen receptor T cell therapy: Shanghai Unicar-Therapy Bio-medicine Technology
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I/II)
- Comparative Analysis
- AUTO3: Autolus
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Pre-clinical and Discovery Stage Products
- Comparative Analysis
- Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Anti-CD22 Therapies Key Companies
- Anti-CD22 Therapies Key Products
- Anti-CD22 Therapies- Unmet Needs
- Anti-CD22 Therapies- Market Drivers and Barriers
- Anti-CD22 Therapies- Future Perspectives and Conclusion
- Anti-CD22 Therapies Analyst Views
- Anti-CD22 Therapies Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.